TP53 and cancer: Some special agents, such as the NQO1 bioactivatable β-lapachone, the DNA methyltransferase-1 inhibitor guadecitabine, or a p53 activator APR-246, have been shown to increase oxidative pressure specifically in cancer cells, which also sensitized cancer cells to PARP inhibitors (Deben et al., 2016; Huang et al., 2016; Pulliam et al., 2018).